Kyntra Bio stock costs EUR 5.00 at a USD 22.6 million market value

Published on 10/15/2026 at 19:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Its range was USD 5.34 to USD 11.65 on October 15, 2026. Kyntra Bio stock costs EUR 5.00 on October 15, 2026, up 0.45 percent on Nasdaq.

Valuation and trading position

Market capitalization stood at USD 22.6 million on October 15, 2026.
Cash and investments reached USD 52.7 million in the second quarter of 2026.
Kyntra Bio stock costs EUR 5.00 at Lang & Schwarz on October 15, 2026 at 6:58 p.m. CEST, up 0.45 percent on Nasdaq.
Kyntra Bio had a P/E ratio of 0.10 on October 15, 2026.

KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio's market capitalization stood at USD 22.6 million on October 15, 2026. The stock's Nasdaq quote was up 0.45 percent on the day, while the euro price at Lang & Schwarz ended the German trading window at EUR 5.00 at 6:58 p.m. CEST.

Cash supports the next milestones

Investing.com reported on October 13, 2026 that Kyntra Bio held USD 52.7 million in cash and investments after an accelerated royalty-financing payment. The same report said the company was seeking funding for a Phase 3 trial and expected interim data from its Phase 2 program in the fourth quarter of 2026.

The financial position is the more useful market statistic than the headline valuation. Kyntra Bio's second-quarter 2026 cash and investments exceeded its USD 22.6 million market capitalization by USD 30.1 million, although the comparison uses a balance-sheet figure and an equity-market figure with different economic meanings.

Price remains above the yearly low

The Nasdaq quote was USD 5.59 on October 15, 2026 at 12:43 p.m. ET, with a previous close of USD 5.57. The 52-week range was USD 5.34 to USD 11.65, placing the quote USD 0.25 above the low and USD 6.06 below the high. Trading volume was 15,954 shares against an average of 18,712.

For investors, the range shows a stock still positioned near the lower end of its annual band. Kyntra Bio's EUR 5.00 Lang & Schwarz quote is a German-market indication, while the Nasdaq figures remain separate home-market context.

Valuation and peer comparison

The quoted P/E ratio was 0.10 and the dividend yield was 0.00 percent on October 15, 2026. The reported cash position and the planned clinical milestones therefore matter more to the trading picture than income-based valuation alone.

Comparison with peers

Kyntra Bio (Nasdaq, USD): up 0.45 percent, P/E 0.10, market capitalization USD 22.6 million.

Crinetics Pharmaceuticals (Nasdaq, USD): unchanged, P/E minus 16.82, market capitalization USD 9.0 billion.

Rocket Pharmaceuticals (Nasdaq, USD): up 3.62 percent, P/E minus 13.43, market capitalization USD 251.4 million.

Next milestones remain dated

The next visible clinical milestone is interim data from the FG-3246 Phase 2 program, expected in the fourth quarter of 2026, according to Investing.com. No exact reporting date is used here.

German price and Nasdaq context

The Nasdaq quote of USD 5.59 on October 15, 2026 was an intraday home-market value, while the German-market price was EUR 5.00 at Lang & Schwarz on the same date at 6:58 p.m. CEST. The two currencies and venues are shown separately.

The further course of trading is shown by the continuously updated real-time quote of Kyntra Bio stock.